X-XSS-Protection: 1; mode=block X-Content-Type-Options: nosniff Strict-Transport-Security: max-age=63072000; includeSubDomains; preload

Edinburgh Molecular Pharmaceuticals

EM Pharmaceuticals is developing a pipeline of highly novel in vivo c-Met targeting theragnostic agents that will alter the landscape of precision medicine.

Edinburgh Molecular Imaging

Using its proprietary platform technology, EM Imaging is developing clinical stage highly novel in vivo c-Met targeting optical imaging agents for early cancer detection and surgery guidance.